at-home testing
[Since this article was published, the FDA has released an alert warning that it has not yet authorized any COVID-19 home testing kits]
The new tool is a clinical-grade ACR test used to identify chronic kidney disease.
The company, which is growing 100% year over year, has now brought in a total of $8.2 million in funding.
The funding will support the Israeli company's push into US markets.
The New York City-based company will be scaling its brand, expanding its logistics and continuing work on its core technology.
The new money will be put toward further expansion of the digital platform and scaling brand partnerships.